COMPASS THERAPEUTICS INC (CMPX) Stock News

USA - NASDAQ:CMPX - US20454B1044 - Common Stock

3.78 USD

-0.32 (-7.8%)

Last: 10/29/2025, 8:21:03 PM

3.8787 USD

+0.1 (+2.61%)

After Hours: 10/29/2025, 8:21:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CMPX Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming September Investor Events

3 months ago - By: Compass Therapeutics

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

3 months ago - By: Compass Therapeutics

Compass Therapeutics Announces Proposed Public Offering

3 months ago - By: The Motley Fool

Compass Therapeutics Posts Wider Q2 Loss

3 months ago - By: Compass Therapeutics

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

3 months ago - By: Benzinga - Mentions: SPHR ARQ DOLE TELA ...

Earnings Scheduled For August 11, 2025

3 months ago - By: Compass Therapeutics

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

a year ago - By: BusinessInsider

News Image

CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024

a year ago - By: InvestorPlace

CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024

3 months ago - By: Yahoo Finance - Mentions: COMP

Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline

6 months ago - By: Compass Therapeutics

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

6 months ago - By: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming May Investor Events

6 months ago - By: Compass Therapeutics

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

6 months ago - By: Compass Therapeutics

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

7 months ago - By: Compass Therapeutics

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

7 months ago - By: Benzinga

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer

8 months ago - By: Compass Therapeutics

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

a year ago - By: Compass Therapeutics

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

a year ago - By: Compass Therapeutics

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

a year ago - By: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming Investor Events

a year ago - By: Compass Therapeutics

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

a year ago - By: Compass Therapeutics

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

a year ago - By: Compass Therapeutics

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

a year ago - By: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming Investor Events

a year ago - By: Compass Therapeutics

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

a year ago - By: Compass Therapeutics

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

a year ago - By: Compass Therapeutics

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

a year ago - By: Compass Therapeutics

Compass Therapeutics Announces CEO Transition